Life Sciences Litigation Insights: April 2022
CRA’s Life Sciences Litigation team provides periodic summaries of notable developments in litigation. In this issue, we share notable cases from 2021 and...
Our team leverages its deep industry knowledge and familiarity with health-care data analytics to help our clients navigate government and regulatory investigations involving civil, criminal, and regulatory enforcement issues. We have expertise in pharmaceutical pricing and reimbursement and the intersection of these areas with government regulations. CRA has experience working with complex data, including Medicare, Medicaid, and private insurance claims data, pharmaceutical sales data, and market research to investigate questions of wrongful conduct, causation and damages. Our experts also serve as monitors during post-merger activities.
Engagements
- 01Assessment of competitive effects in branded pharmaceutical mergerA CRA expert provided input to the Canadian Competition Bureau in its evaluation of the proposed merger of two branded pharmaceutical manufacturers. CRA’s team...View engagement
- 02CRA addresses U.S. government healthcare programs and pharmaceutical pricing in False Claims Act suitIn this whistleblower suit, a relator alleged Bristol-Myers Squibb Co. (“BMS”) violated the False Claims Act and various state claims. The suit alleged that...View engagement
- 03CRA consultants assess distributor practices for controlled substancesCRA was retained by distributors of pharmaceutical products in national litigation relating to opioid products. CRA addressed claims by state and local...View engagement